Thierry Schlama

Title: Innovations and Contributions of Thierry Schlama

Introduction

Thierry Schlama is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of chemical synthesis, particularly in the development of neprilysin inhibitors. With a total of 4 patents to his name, Schlama's work has had a substantial impact on pharmaceutical research and development.

Latest Patents

Schlama's latest patents include a process and intermediates related to a new chemical synthesis. This invention focuses on the preparation of the neprilysin (NEP) inhibitor sacubitril. It also introduces new intermediate compounds and their applications in this innovative chemical synthesis route. Another significant patent involves an enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or their prodrugs. This process particularly emphasizes NEP inhibitors that comprise a γ-amino-δ-biphenyl-α-methylalkanoic acid or acid ester backbone.

Career Highlights

Thierry Schlama is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on advancing therapeutic solutions through innovative chemical processes. His expertise in chemical synthesis has positioned him as a key contributor to the development of new pharmaceutical compounds.

Collaborations

Throughout his career, Schlama has collaborated with several esteemed colleagues, including Florian Karl Kleinbeck-Riniker and Thomas Ruch. These collaborations have fostered a productive environment for innovation and have led to the successful development of various chemical processes and compounds.

Conclusion

Thierry Schlama's contributions to the field of chemical synthesis and his innovative patents have significantly advanced the development of neprilysin inhibitors. His work continues to influence pharmaceutical research, showcasing the importance of innovation in healthcare.